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Abstract: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder whose aetiology is
still unknown. Most hypotheses point out the gut-brain axis as a key factor for IBS. The axis is com-
posed of different anatomic and functional structures intercommunicated through neurotransmitters.
However, the implications of key neurotransmitters such as norepinephrine, serotonin, glutamate,
GABA or acetylcholine in IBS are poorly studied. The aim of this review is to evaluate the current
evidence about neurotransmitter dysfunction in IBS and explore the potential therapeutic approaches.
IBS patients with altered colorectal motility show augmented norepinephrine and acetylcholine levels
in plasma and an increased sensitivity of central serotonin receptors. A decrease of colonic mucosal
serotonin transporter and a downregulation of α2 adrenoceptors are also correlated with visceral
hypersensitivity and an increase of 5-hydroxyindole acetic acid levels, enhanced expression of high
affinity choline transporter and lower levels of GABA. Given these neurotransmitter dysfunctions,
novel pharmacological approaches such as 5-HT3 receptor antagonists and 5-HT4 receptor agonists
are being explored for IBS management, for their antiemetic and prokinetic effects. GABA-analogous
medications are being considered to reduce visceral pain. Moreover, agonists and antagonists of
muscarinic receptors are under clinical trials. Targeting neurotransmitter dysfunction could provide
promising new approaches for IBS management.
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1. Introduction
Irritable bowel syndrome (IBS) is defined as a functional gastrointestinal disorder,
whose main symptoms are recurrent abdominal pain, changes in the frequency or charac-
teristics of stool and abdominal distension. As a functional gastrointestinal disorder, IBS
does not have a morphologic, metabolic, or neurologic aetiology. It is diagnosed using
Rome IV clinical parameters. IBS can be classified in 4 different subtypes according to
patient’s bowel habit: IBS with predominant constipation (IBS-C), IBS with predominant
diarrhoea (IBS-D) and mixed-IBS which alternates between diarrhoea and constipation
(IBS-M). Another type of IBS is called unclassified (IBS-U) [1], where individuals who do
not fall into the other intestinal pattern categories are included.
IBS is considered the most prevalent gastrointestinal disorder; its prevalence is esti-
mated to be around 10% to 15% of the population in Europe and North America. Despite its
high prevalence, the physiopathology of IBS is still unknown. There are many hypotheses
about IBS aetiology: psychosocial disorders, microbiotic alterations, hypersensitivity to
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some food, intestinal motility disorders, changes in visceral pain perception, or neuro-
transmitter alterations, creating a complex disorder of the gut-brain axis [2]. This axis is
composed of intestinal microbiota, the intestinal epithelial barrier, neurotransmitters, the
central nervous system (CNS), enteric nervous system (ENS), autonomic nervous system,
and the hypothalamic-pituitary-adrenal axis. Together, all these components communicate
bidirectionally (mainly through neurotransmitters), so intestinal signals can influence brain
functions and vice versa. In fact, IBS patients show differences in brain activation areas
in response to rectal distension and pain compared with healthy controls; suggesting that
IBS patients lack central activation of descending inhibitory pathways [3]. Recent studies
have reported alterations in brain networks and networks of interacting systems in the
gut in IBS patients, evidencing a potential role of neurotransmitters on IBS pathophysi-
ology [4]. On the other hand, psychosocial factors such as stress, anxiety, or depression,
where neurotransmitters can play a key role, are considered risk factors for IBS and may
even contribute to an exacerbation of IBS symptoms [5].
In recent years, many studies have focused on the association between IBS and changes
in gut microbiota [6]. Gut microbiota can modulate host production of different neuro-
transmitters, as well as produce some neurotransmitters themselves [7]. Gut microbiota
could play a role in the aetiology of IBS as they influence intestinal motility, gastrointestinal
physiology, neurotransmitter levels, and behaviour. Actually, germ-free rats display a delay
in intestinal peristalsis and that can be reverted by colonization with Lactobacillus acidophilus
or Bifidobacterium bifidum [8]. As demonstrated in several studies, IBS patients show per-
turbed microbiota composition, although there is no common microbiotic signature among
IBS patients [9]. An increase of Firmicutes, especially Clostridium and Ruminococcaceae with
a decrease of Bacteroidetes, particularly Bifidobacteria can be obtained in several mucosal and
faecal samples from IBS patients [10]. Moreover, preliminary data suggest correlations of
regional brain structural differences with gut microbial taxa [4].
The pathophysiology of IBS is incompletely understood, but it is well established that
alterations in the gut-brain axis, altered CNS processing, motility disturbances and visceral
hypersensitivity contribute to IBS aetiology. Other, less relevant or less studied mechanisms
involved in IBS include genetic associations, alterations in gastrointestinal microbiota,
cultural factors, and disturbances in mucosal and immune function [11]. Alterations in
the gut-brain axis and differences in brain function are major contributing factors to IBS
aetiology; however, the implications of key neurotransmitters such as norepinephrine (NE),
serotonin, glutamate, GABA, and acetylcholine (ACh) in IBS are still unknown. The aim
of this review is to evaluate the current evidence about neurotransmitter dysfunction in
IBS and explore its potential therapeutic treatment. The Rome IV criteria for the diagnosis
of IBS consist of abdominal pain associated with an alteration in either stool form or
frequency, occurring for at least 6 months. Neurotransmitter dysfunctions could contribute
to IBS and some of its most prevalent symptoms used for its diagnosis, grouped into
two main aspects, visceral hypersensitivity and altered motility (Figure 1), although they
may also be involved in other symptoms such as diet-related digestive disturbances,
psychosocial disturbances, anxiety, depression, fatigue, hypertension, dyslipidaemia, etc.
Therefore, targeting those dysfunctions may open novel lines for IBS management, taking
into account, that these symptoms may also be indirect effects mediated by other biological
and psychological factors.




Figure 1. Neurotransmitter dysfunctions are related to some gastrointestinal IBS symptoms. Vis-
ceral hypersensitivity has been correlated to decreased glutamine levels, lower levels of GABA in 
the anterior cingulate cortex, higher levels of 5-hydroxy-indol acetic acid, increased expression of 
high affinity choline transporter, downregulation of α-2 adrenoceptors, augmented sensitivity of 
central serotonin receptors and lower levels of mucosal SERT. The latter 3 alterations can also be 
found in altered colorectal motility together with higher levels of NE in plasma, activation of α-1 
adrenoceptors and higher levels of ACh. We notate neurotransmitter’s families with colours: red- 
norepinephrine; blue- 5-HT; green- GABA; orange-acetylcholinergic. 
2. Norepinephrine 
NE, also known as noradrenaline, is a key catecholamine with multiple physiological 
and homeostatic functions, key in the sympathetic nervous system. It is involved in exci-
tation and the alert state during awake time, and in sensory signal detection. Secondarily, 
NE plays a role in behaviour, memory, attention, and learning. In fact, NE depletion in 
rats triggers distractibility and attentional deficits [12]. NE also has a leading role in spatial 
working, and memory functions, and its level is correlated with cognitive performance. 
2.1. Norepinephrine in the Central Nervous System 
Noradrenergic neurons come from the locus coeruleus, and their axons reach many 
brain regions. NE improves long-term memory consolidation, influences the processing 
of sensory stimuli in the amygdala and hippocampus, and also regulates working 
memory and attention in the prefrontal cortex [13]. There are 3 types of adrenergic recep-
tors, which NE can interact when is released from ascending fibres: the stimulatory α1 
and β adrenoceptors, and the inhibitory α2 adrenoceptor. Among those receptors, NE has 
a higher affinity for α2, which has 3 subtypes: α2A, α2B and α2C. Although α2-adreno-
ceptors are found postsynaptically, subtypes α2A and C are predominantly presynaptic 
[14]. There are also 3 subtypes of α1-adrenergic receptors, α1A, α1B and α1D, for which 
NE has lower affinity. Stimulation of those receptors enhances excitatory processes, espe-
cially in the somatosensory cortex. β-receptors are divided into 3 types: β1, localized in 
the heart, β2 in the lungs and β3 in stomach and adipose tissues. They are also expressed 
in the CNS; however, NE has low affinity for these types of receptors. Electromagnetic 
Figure 1. Neurotransmitter dysfunctions are related to some gastrointestinal IBS symptoms. Visceral hypersensitivity
has been correlated to decreased glutamine levels, lower levels of GABA in the anterior cingulate cortex, higher levels of
5-hydroxy-indol acetic acid, increased expression of high affinity choline transporter, downregulation of α-2 adrenoceptors,
augmented sensitivity of central serotonin receptors and lower levels of mucosal SERT. The latter 3 alterations can also
be found in altered colorectal motility together with higher levels of NE in plasma, activation of α-1 adrenoceptors and
higher levels of ACh. We notate neurotransmitter’s families with colours: red- norepinephrine; blue- 5-HT; green- GABA;
orange-acetylcholinergic.
2. Norepinephrine
NE, also known as noradrenaline, is a key catecholamine with multiple physiological
and homeostatic functions, key in the sympathetic nervous system. It is involved in excita-
tion and the alert state during awake time, and in sensory signal detection. Secondarily,
NE plays a role in behaviour, memory, attention, and learning. In fact, NE depletion in rats
triggers distractibility and attentional deficits [12]. NE also has a leading role in spatial
working, and memory functions, an ts level is correlated with ognitive performance.
2.1. Norepinephrine in the Central Nervous System
Noradrenergic neurons come from the locus coeruleus, and their axons reach many
brain regions. NE improves long-term memory consolidation, influences the processing of
sensory stimuli in the amygdala and hippocampus, and also regulates working memory
and attention in th prefrontal cortex [13]. There are 3 types of adrenergic receptors,
which NE can interact when is released from ascending fibres: the stimulatory α1 and β
adrenoceptors, and the inhibitory α2 adrenoceptor. Among those receptors, NE has a higher
affinity for α2, which has 3 subtypes: α2A, α2B and α2C. Although α2-adrenoceptors are
found postsynaptically, subtypes α2A and C are predomin ntly presyn ptic [14]. There are
also 3 subtypes of α1-adrenergic receptors, α1A, α1B and α1D, for which NE has lower
affinity. Stimulation of those receptors enhances excitatory processes, especially in the
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somatosensory cortex. β-receptors are divided into 3 types: β1, localized in the heart,
β2 in the lungs and β3 in stomach and adipose tissues. They are also expressed in the
CNS; however, NE has low affinity for these types of receptors. Electromagnetic studies in
primates have found β2-receptor expression on dendritic spines in the prefrontal cortex
and on GABAergic interneurons; on glia, these β-receptors reduce glutamate reuptake
and regulate glucose availability [15]. Similarly, other studies have demonstrated that
β-receptors could enhance GABAergic processes in the somatosensory cortex [16].
2.2. Norepinephrine’s Role in the Gastrointestinal System
In the peripheral nervous system, noradrenergic neurons respond to stress via sym-
pathetic. Higher levels of epinephrine or NE can increase heart rate (via β1-receptors),
pulmonary function (via β2-receptors), and blood pressure (via α1- and β-receptors) to in-
crease the amount of oxygenated blood in striated muscle [17]. Via β3-receptors, digestive
function is reduced. However, acute stress in mice stimulates colonic contractile activity
almost immediately for defecation [18]. Presynaptic inhibition of NE is the main role of
an α2A-adrenoceptor. Decreased levels of this receptor and NE transporter (NET) were
found in colon of IBS rats, resulting in an increased release of NE [19]. Moreover, α2A
and α2C polymorphisms are associated with constipation and high somatic symptoms
in patients with lower functional gastrointestinal disorders [20]. This genetic variation
in α2-adrenoceptors could influence not only visceral sensation and stool frequency (es-
pecially in IBS-C), but also behaviour in IBS patients. Noradrenaline also seems to affect
colorectal motility. The intrathecal injection of noradrenaline induces a propulsive motility
through activation of α1-adrenoceptors on sacral parasympathetic preganglionic neurons
in rats [21]. In contrast, intrathecal injection of prazosin (α1-adrenoceptor antagonist)
presents no effects on colorectal motility, confirming that noradrenergic descending path-
way from the brain influences gastrointestinal motility by acting on the lumbosacral spinal
defecation centre.
Intestinal NE can increase the pathogenicity of some bacteria. Pathological Escherichia
coli O157:H7 (EHEC’s) growth is enhanced by the presence of dopamine and NE in in-
testinal lumen. NE also increases motility, the ability to create biofilm, and virulence of
EHEC [22]. In turn, gut microbiota can influence NE levels in intestinal lumen, but it is
still undetermined whether bacteria can produce NE themselves or only modulate host
production [23]. Germ-free mice show lower levels of NE in caecal tissue. Those mice also
present behavioural changes that can be reverted by probiotics. These data support the
relation between microbiota and neurotransmitters [24] and highlight microbiota’s role
in the gut-brain axis. Using microbiota modulation as a source of neurotransmitters to
coordinate neurological function could be an interesting approach to study.
Stress could be a risk factor for IBS development. There are 3 main mediators of
stress: corticotropin releasing hormone, corticosterone, and NE. Plasma concentrations
of corticosterone and NE were significantly higher after 9-day mild stress in rats [25].
Although it is known that IBS patients usually report higher levels of psychological distress,
Deechakawan W. et al. found no relation between the improvement of psychological
symptoms and norepinephrine levels in urine [26]. Similarly, other studies revealed no
differences in blood cathecolamin levels during sleep. However, differences between IBS
subtypes were found: women with IBS-C displayed significantly increased NE, epinephrine
and cortisol levels throughout the sleep interval, and women with IBS-D presented lower
levels of NE and cortisol [27]. Chronic stress in rats increases α1C subunit of Cav1.2 chan-
nels in colonic muscularis. These changes are expressed clinically as accelerated colonic
transit and increased defecation rate. Actually, NE induces colonic circular smooth mus-
cle hyperreactivity to acetylcholine [18]. In agreement, an inverse relationship between
parasympathetic tone and epinephrine plasma levels in IBS patients has been observed [28].
However, NE alterations are not clear, as some studies have shown higher levels of nore-
pinephrine in blood, urine and saliva in IBS patients [29]. Berman et al. [29] demonstrated
that IBS patients had higher plasma NE levels than healthy controls before and after inges-
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tion of yohimbine (α2A-adrenoreceptor antagonist) and clonadine (α2A-adrenoreceptor
agonist). That augmentation of noradrenergic activity can be explained by a downregula-
tion of presynaptic inhibitory α2A-receptors. Both phenomena (higher plasma NE levels
and downregulation of presynaptic inhibitory α2A-receptors) were correlated with anxiety
disorders [30].
Enzymes from the noradrenergic system have also been studied in IBS, including
tyrosine hydroxylase (TH), whose function is rate-limiting norepinephrine production.
TH expression seems to be increased in IBS-D rats, although the augmentation was non-
significant [31]. Chronic stress also enhances TH expression in the adrenal gland, which
manifests in an increase of NE release in response to stressors in rats [32]. IBS patients with
depression display changes in TH gene expression, as well [33]. These findings suggest
that some drugs such as reboxetine, which strengthens the adrenergic system may play a
role in the treatment of IBS patients with depressive disorders.
2.3. Norepinephrine as a Target for Treatment
Preliminary clinical results support a possible therapeutic role for the α2-adrenoreceptor
in IBS. A study investigated modifications of NE plasma levels after ingestion of the α2-
receptors antagonist, yohimbine (YOH) and agonist clonidine (CLO). The results showed
that YOH increased NE plasma levels and anxiety in IBS patients, while CLO decreased
NE plasma levels and was associated with more brain activity [30]. Another possible line
of treatment focuses on the Corticotrophin Release Factor- Receptor type 1 (CRF-R1). IBS
patients present alterations in NE pathways of locus coeruleus complex, and CRF-R1 could
attenuate the locus coeruleus complex responsiveness to stressors [34]. The vagus nerve
could also be a target for IBS treatment. A vagal reinforcement can be achieved by different
techniques as electrical or pharmacological stimulation. Moreover, nonpharmacological
approaches such as hypnotherapy or mindfulness seem to increase vagal tone. Visceral
pain perception may also be improved by these therapies which reduce epinephrine and
TNF-α levels allowing remission maintenance [28].
3. Serotonin
Serotonin was previously called enteramin by Erspamer and Asero due to its gastroin-
testinal functions; after discovering that it was identical to the vasoconstrictor substance
known as such, it was renamed serotonin (5-HT, 5-hydroxytriptamin). Serotonin is syn-
thesized from the amino acid tryptophan in enterochromaffin cells from the intestinal
epithelium and serotonergic neurons. Ninety-five percent of serotonin production is from
the gastrointestinal tract, meanwhile, 5% is from the nervous system. Once in the blood,
serotonin can be stored in platelets, in which there are high levels of SERT (serotonin
transporter) [35]. SERT uptakes 5-HT into cells, where it can be stored or degraded. SERT
function is key to regulate 5-HT’s availability, and consequently 5-HT signalling.
Serotonin has multiple functions at the digestive level as a modulator of gastrointesti-
nal secretion, peristalsis, or absorption; and also at a central level, controlling behaviour
and critical neurological functions [36]. Experimental exogenous intake of serotonin results
in multiple responses. This wide range of effects is due to the vast localization and diver-
sity of 5-HT receptors [37]. Fourteen different 5-HT receptors have been identified and
clustered in seven families based on their signalling pathways. Most of them are coupled
to G proteins, and only the 5-HT3 receptor is a ligand-gated ion channel [38]. It is now
known that some 5-HT receptors have specific functions, although many of them trigger
diverse and antagonistic responses [39].
3.1. Serotonin’s Role in the Central Nervous System
In the CNS, 5-HT regulates numerous functions such as nociception, motor tone, sleep,
sexual behaviour, emesis, and temperature. It also affects vascular tone as a vasoconstrictor
molecule, helping other vasoactive mediators as angiotensin II, histamine and NE [40].
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Moreover, alterations in the serotonergic system are correlated to some psychiatric
diseases such as depression or anxiety disorders. Activity of 5-HT2C receptors seems to
increase anxiety [41], and platelet 5-HT levels are increased in patients suffering from
anxiety and depression [42]. Almost all serotonin receptors play a role in depression
and anxiety-like behaviours. Activation of postsynaptic 5-HT1A, 5-HT1B, 5-HT2B and
5HT4 receptors and inhibition of postsynaptic 5-HT2A, 5-HT3, 5-HT5A and 5-HT7 result in
antidepressant-like effects [43].
3.2. Serotonin’s Role in the Gastrointestinal System
The release of 5-HT from enterochromaffin cells in the intestinal epithelium occurs
mainly after mechanical and chemical stimulus of the intestinal wall when food passes
through the intestine [44]. Intestinal microbiota are an essential regulator of 5-HT, as they
increase the expression of tryptophan hydroxylase enzymes [7] and regulate serotonin
transporter function [45]. 5-HT release can also be regulated by vagal or sympathetic
adrenergic stimulation, mucosal changes, obstruction of gut motility or lowering of luminal
pH [46]. After its release, 5-HT stimulates the peristaltic reflex, increases ileal and duodenal
irrigation and facilitates gastric accommodation mediated by 5-HT1, 5-HT3, 5-HT4 and
5-HT7 receptors [47]. To avoid serotonin overstimulation, 5-HT is afterwards taken up by
SERT from enterocytes.
There are 3 main 5-HT receptors involved in the regulation of gastrointestinal func-
tions: 5-HT1, 5-HT3 and 5-HT4. Activation of 5-HT1A receptors (mainly localized in
submucosally and in the myenteric plexus of the ENS) inhibits ACh release, which leads to
a reduction of intestinal smooth muscle contraction–an anticholinergic effect [35]. These re-
ceptors are located in the spinal cord as well, where their main function is to reduce somatic
pain signalling [48]. 5-HT3 receptors (situated in enteric neurons and smooth muscle cells)
intervene in the contraction of intestinal smooth muscle (modulating gut motility) and in
gut-brain communication through vagal afferent fibres, activating pain-mediating neurons
(modulating visceral pain signalling) [49]. The 5-HT3 receptor also mediates nociception
by activation of inhibitory GABAergic interneurons. Some polymorphisms of this receptor
may be associated with IBS-D risk [50]. In fact, the gastrointestinal serotonergic system has
been widely associated with some IBS alterations.
Enterochromaffin cells and 5-HT are increased in colonic tissue from IBS rats. In
addition, that increment is correlated to higher c-fos levels in CNS. This evidence sustains
that CNS activation may induce enterochromaffin cells activation in the colon and sub-
sequent 5-HT release [33]. IBS-D patients show significantly elevated serotonin levels in
blood and urine compared with controls and IBS-C patients [51]. However, high sero-
tonin levels do not seem to be specific to an IBS subtype, as other studies have detected
increased 5-HT concentrations in both IBS-C and IBS-D patients [52]. IBS patients show
lower concentrations of the main 5-HT metabolite, 5-HIAA (5-hydroxyindole acetic acid),
and a lower 5-HIAA/5-HT ratio [46], although hypersensitive IBS patients show increased
concentrations of 5-HIAA compared with non-hypersensitive ones [53]. A gender influ-
ence on 5-HIAA levels and 5-HIAA/5-HT ratio was found in IBS patients, with levels
significantly lower in female than male IBS patients. According to IBS subtypes, IBS-M
patients displayed the lowest 5-HIAA and 5-HIAA/5-HT ratios compared to IBS-D and
IBS-C patients [54]. Moreover, significant differences in the ratio of 5-HIAA/HVA (ho-
movanillic acid, a dopamine metabolite) have been demonstrated among IBS subtypes:
IBS-C patients have higher levels of dopamine in plasma and of dopamine metabolites in
their urine. 5-HIAA was not the only serotonin metabolite studied, 5-HTP might play a
role in hyperalgesia [55]. Lower densities of endocrine cells expressing 5-HT and peptide
YY in the colon tissues of IBS patients have been also demonstrated, as well as a reduction
of chromogranin A density in the colon of patients with IBS [56].
Some SERT polymorphisms are responsible for pharmacokinetic differences that are
observed, for example, in the response of colonic transit to alosetron in IBS-D patients [57].
IBS symptoms including luminal hypersensitivity, augmented peristalsis, or diarrhoea
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might be explained by changes in SERT expression. Mucosal SERT expression decreases
in IBS-C and IBS-D patients. This increases mucosal 5-HT, which could mediate those
symptoms [58]. Furthermore, a decrease of mucosal SERT expression is correlated with an
increase of mucosal intraepithelial lymphocytes and mast cells in IBS-D patients [59]. The
activity of platelet SERT has also been examined with some controversial results. Some
studies have shown reduced platelet SERT expression in IBS patients, but other studies have
found a reduction only in male IBS patients [60]. Genetic variations in SERT expression
are being studied as a possible aetiology for IBS development, hypothesizing a genetic
predisposition to IBS. In fact, it was demonstrated that SERT variants could be correlated
in IBS patients with psychiatric comorbidities [59]. Interestingly, ethnic differences were
found in specific genetic variations. The L/L genotype or the L allele was more frequent in
East Asians than in Caucasians with IBS-C, and SLC6A4 polymorphism was found to be
associated with a reduced risk of IBS in American and Asian populations [59].
Many studies have described changes in serotonin metabolism in patients with psy-
chiatric comorbidity, but according to Thijssen et al., there is no change in plasma 5-HT
metabolites caused by anxiety or depression symptoms [46]. Changes in tryptophan
metabolism have been correlated with the manifestation of depressive symptoms in pa-
tients with IBS as well. Decreases in kynurenic acid and 5-HT were observed in duodenal
mucosa from IBS patients, and these changes were correlated with their psychological state.
These data suggest that modulation of the kynurenine/tryptophan pathway influences
NMDA receptors in CNS regions involved in the development of depression and may
provide useful therapeutic tools to prevent or reduce psychiatric comorbidities of IBS [61].
It must be known that, due to the multifactorial physiopathology of IBS, single-
receptor-modulating drugs may not reach enough therapeutic gain. Almost 67% of IBS
patients associate their symptoms with diet. A decrease in the intake of foods rich in
FODMAPs increases the density of 5-HT and peptide YY in endocrine cells and improves
symptoms and quality of life for IBS patients [56]. Other possible diets base on tryptophan
modifications have been proposed, as serum tryptophan levels are increased in D-IBS
patients compared to healthy controls. However, a dairy-free diet does not change these
alterations or eliminate IBS symptoms [62]. Otherwise, kynurenine/tryptophan and mela-
tonin/tryptophan ratios are decreased in IBS-D patients compared to healthy controls, with
the latter ratio directly correlated to altered sleep quality in IBS-D patients [63].
3.3. The Serotonergic System as a Target for Treatment
Promising IBS management results using agonists and antagonists of 5-HT3 and 5-HT4
receptors are being explored [64]. Cisapride is a prokinetic drug, a partial 5-HT4 receptor
agonist, 5-HT3 receptor antagonist, and HERG K+ channel blocker. Its effects on smooth
gut muscle may be paradoxically due to the blockage of the HERG K+ channel; this action
is also the cause of its proarrhythmic effect [65]. Tegaserod is a 5-HT4 agonist that is
already used to treat IBS-C in women in some parts of the world. As with cisapride, it
has prokinetic effects [47] and decreases abdominal contractions during colorectal balloon
distension in mice [66]. Other studied 5-HT4 agonists are velusetrag and prucalopride
which seem to be effective for constipation [67]. Alosetron is approved in the United States
for the treatment of female IBS-D patients. It is a 5-HT3 receptor antagonist and reduces
abdominal pain [68]. It is suggested that alosetron’s effect may occur on the CNS instead of
peripherally. PET scans show that alosetron reduces cerebral blood flow in the left anterior
insula and inhibits the ventromedial frontal cortex, indicating that alosetron may repress
autonomic and emotional processing networks. It was also demonstrated that alosetron
and granisetron could cross the blood-brain barrier, supporting the idea that the effect
of those drugs is centrally mediated [69]. Granisetron was tested in mice, demonstrating
that it could blockade 5-HT-induced hypersensitivity [53]. Ondansetron and Ramosetron
are also 5-HT3 antagonists. Ramosetron is used in Asia as an antiemetic drug, but it is
still not available for therapeutic use in other continents, even though, it is a promising
treatment for IBS-D patients, since it improves stool consistency and reduces urgency and
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frequency of stool [70]. Recently, chanoclavine, a 5-HT3A blocker, has been proposed due
to its potential antiemetic effects [71]. 5-HT1B/D receptor agonists such as sumatriptan
are also under study. Sumatriptan’s intravenous application delays gastric emptying and
causes a significant relaxation of the gastric fundus [72]. In addition to its actions on the
upper gastrointestinal tract, sumatriptan also modifies colonic, rectal, and anal sensitivity.
Despite its effects on gastric function in dyspeptic patients, sumatriptan and other 5-HT1
receptor agonists can have many side effects including constriction of coronary arteries or
induction of chest pain by increasing oesophageal visceral sensitivity. Therefore, its daily
use may not be possible [73].
Selective serotonin reuptake inhibitors (SSRIs) are a group of antidepressant drugs
that include fluoxetine, paroxetine, citalopram, and sertraline, among others. Their increase
on serotonergic activity is mainly due to SERT inhibition. There are contradictory studies
about the effects of those drugs on 5-HT plasma levels in IBS patients. Some studies
affirm that administration of citalopram in IBS patients leads to an increase of 5-HT plasma
levels, but it is still unknown how this increase may change 5-HT activity at the CNS or
intestinal levels [74]. There is conflicting information about the use of antidepressants
to treat functional gastrointestinal disorders [75]. Although some of them improve IBS
symptoms, their side effects can reduce their applicability to treat IBS. Actually, venlafaxine
(a serotonin-NE reuptake inhibitor) improves gastric and colonic symptoms but can also
cause fatigue, hypertension or dyslipidemia [75]. Moreover, there is some controversy also
exists regarding citalopram’s efficacy in treating IBS symptoms compared to placebo [76,77].
Other SSRIs have been studied with diverse results. Paroxetine enhanced patients’ per-
ception of well-being, but did not ameliorate abdominal symptoms [78]. In contrast, some
studies found that fluoxetine improves abdominal symptoms and stool frequency in IBS-C
patients [79]. Patients treated with low doses of amitriptyline (a tricyclic antidepressant)
reported amelioration of all symptoms [80]. All these data suggest that SSRIs could be
a useful treatment for IBS, but more clinical trials and studies are needed to clarify the
controversial results [81].
4. Glutamate
Glutamate is the main excitatory neurotransmitter in the CNS [82], and it has been
described as having multiple roles as a nutrient, catalytic intermediate, or excitatory
molecule [83]. Glutamate is an amino acid that can be introduced exogenously through the
diet; however, exogenous glutamate crosses neither the intestinal barrier nor blood-brain
barrier. Glutamate as a neurotransmitter is produced de novo in the brain from glucose [84].
After glutamate release from neurons, this amino acid is taken up by glia cells, and there,
it is turned to glutamine by glutamine-synthetase for recycling to neurons. Glutamate
reserves are refilled again when glutamine is engrossed by neurons. This means glutamine
metabolism is the principal cycle for replacement of glutamate in neurons [85]. A high
protein diet decreases glutamate and glutamine concentrations in plasma, although this
phenomenon is still unexplained [86].
4.1. Glutamate in the Central Nervous System
In the CNS, glutamate plays a role in learning, motor activity, memory, neural devel-
opment and synaptic plasticity [84]. Its involvement in processing pain was demonstrated
through the measurement of glutamate levels in cerebrospinal fluid because higher levels
of glutamate are correlated to heavy pain [87].
Glutamate receptors are divided into ionotropic glutamate receptors (iGluRs) and
metabotropic glutamate receptors (mGluRs). In turn, mGluRs are clustered in 3 groups: I, II,
and III [88]. Receptors belonging to groups II and III act as regulators, inhibiting glutamate
release [89]. Eight different mGluR subtypes (mGluR1 to mGluR8) exist. The first studies
of glutamate supported the theory that its receptors were in the CNS, but recent results
confirmed that mGluRs are also expressed peripherally, such as in the gastrointestinal
system [89]. IGluRs are divided into 3 subtypes: N-methyl-D-aspartate (NMDA), amino-3-
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hydroxy-5-methyl-4-isoxazole propionate, and kainate receptors. Located in the esophagus,
NMDA receptors are involved in the process of swallowing [90]. Depression and anxiety
disorders have been associated with glutamatergic changes, especially in mGluRs, because
effective antidepressants activate this group of glutamate receptors [91].
4.2. Glutamate’s Role in the Gastrointestinal Tract
Glutamate modulates energy metabolism in the gastrointestinal system at pre and
postprandial phases. Glutamate also seems to enhance digestion and nutrient absorption
via brain activation by the vagus nerve [92]. It is conjectured that the glutamate receptor
located in the stomach is mGluR1, and that its role is to stimulate 5-HT release indirectly
through excitation of vagal afferents. On the other hand, glutamate decreases somatostatin
release, stimulating exocrine and endocrine functions in the GI tract [93]. The activation of
mGluR7 increases colonic secretory function, while mGluR8 plays a role in colon motility.
Moreover, mGluR7 could be associated with IBS, because its expression is increased in
colon of rats with visceral hypersensitivity [94]. Glutamate injection into the stomach,
duodenum, and portal vein results in the activation of afferent fibres on the gastric, celiac
and hepato-portal vagal branches. This activation in the stomach seems to stem from the
vagus nerve via 5-HT receptors. In fact, granisetron, a selective inhibitor of the 5-HT3
receptor, can inhibit this response [95].
IBS patients show reduced glutamate and glutamine concentrations, although glu-
tamine was disjointed to psychological or gastrointestinal symptoms [96]. These results are
contradictory regarding pain because glutamate concentrations are elevated in fibromyal-
gia and chronic pelvic pain [97]. Oppositely, lower concentrations of glutamine can be a
predictor of the duration of abdominal pain in IBS patients [98]. Lower glutamate levels
and disruptive glutamate receptors expression could point to glutamate as a possible thera-
peutic target for IBS. In fact, AMN082, a mGluR7 agonist, showed a decrease in colorectal
distension-induced visceral hypersensitivity and a reduction in the inflammatory response
via inhibition of NF-κB in IBS rats [99]. An anxiolytic effect has also been described in the
CNS, modulating GABAergic neurotransmission [100].
Central changes in the glutamatergic system in relation to visceral hypersensitivity
have been studied in animals, showing that rats suffering from induced colitis and visceral
pain manifested increased levels of GluN2B and GluA2 receptors in the anterior cingulate
cortex [101].
4.3. Glutamate as a Target for Treatment
Changes in dietary glutamate have also been studied for the management of IBS and
fibromyalgia. A glutamate-rich diet worsens IBS and fibromyalgia symptoms. Although
different doses of glutamate as nutritional supplement have been investigated for the
treatment of dyspepsia, functional dyspepsia, gastrointestinal ulcer, and diarrhoea with
improvement of symptoms [95], higher dietary glutamate levels have been associated with
abdominal bloating, diarrhoea, and abdominal pain [102]. However, glutamine supple-
mentation seems to be beneficial in some cases. Actually, in IBS-D patients with intestinal
hyperpermeability following an enteric infection, oral dietary glutamine supplements
dramatically and safely reduced all major IBS-related endpoints [103].
mGluR5 has been found peripherally in the gastrointestinal tract. After this discovery,
several trials have emerged targeting those receptors. mGluR5 antagonists such as MPEP or
SIB1893 remove IL-1β-induced mechanical allodynia in rats [104]. MPEP also diminishes
reflux symptoms by inhibiting the transient lower sphincter relaxation. Patients with
gastroesophageal reflux disease reported improvement in acid reflux with the use of
ADX10059 (a mGluR5 negative allosteric modulator) [104]. Moreover, glutamate uptake
activators such as riluzole seem to improve visceral hypersensitivity in stressed animals,
having no effect on naive rats [105]. Nausea and emesis could be treated by the blockade
of non-NMDA iGluRs. In fact, NBQX eliminates salivary secretion and nausea [90]. On the
other hand, antagonists of NMDA receptors could be beneficial for visceral pain, which was
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shown in male mice faced with the hot plate and writhing tests [106]. Despite their useful
pharmacological applications, iGluRs modulators cannot be used as long-term treatment
due to their psychiatric side effects [105].
5. Gamma-Aminobutyric ACID
Gamma-aminobutyric acid (GABA) is an amino acid derivate of glutamate. Glutamic
acid decarboxylase (GAD) enzyme is responsible for the conversion of glutamate to GABA
by α-decarboxylation; afterwards, GAD interacts with the vesicular GABA transporter
mediating the vesicular uptake of GABA [105]. Brain-derived neurotrophic factor (BDNF)
increases GAD expression, regulating GABA homeostasis [106]. Ninety percent of the
GABA synthesized is subsequently degraded by GABA-transaminase, which is present
in neurons and glia cells. After its release from the nervous system, GABA transporter
uptakes GABA from the synaptic cleft.
5.1. GABA in the Central Nervous System
GABA is the primary inhibitory neurotransmitter in the CNS [107]. Its inhibitory
function is shared with the neurotransmitter glycine in the mammalian CNS [108]. It
functions to reduce neuronal excitability by inhibiting nerve transmission. GABAergic
neurons are located in the hippocampus, thalamus, basal ganglia, hypothalamus, and
brainstem. The balance between inhibitory neuronal transmission via GABA and excitatory
neuronal transmission via glutamate is essential for proper cell membrane stability and
neurologic function. GABA is conjectured to have effects on motor performance and
cognitive functioning because a decrease of GABA levels in elderly patients seems to be
associated to the deterioration of these abilities [109]. It also plays a role as a source of
energy, generating ATP in the tricarboxylic acid cycle in the mitochondria [110]. There are
2 main types of GABA receptors: GABA-A (fast-acting ionotropic receptors) and GABA-
B (slower-acting metabotropic receptors) [110]. GABA-A receptors are divided into 19
subunits that can be located in neuronal and nonneuronal cells [111]. They are chlorine
ion channels, whereas GABA-B receptors are G-protein coupled receptors [108]. GABA-A
receptors are localized in synaptic and extrasynaptic sites. Synaptic sites mediate phasic
inhibition and extrasynaptic ones mediate tonic inhibition [112]. Non-neuronal GABA-
receptors play a role in fluid secretion in lungs and intestine [113] while in central nervous
system GABA can play the role of gliotransmitter when it is released from astrocytes [114].
Recent studies have also described a third GABA-receptor: GABA-ρ or GABA-C receptor.
This receptor is also considered a subtype of GABA-A receptor, which is mainly localized
in the eye and involved in visual image processing [115]. Another receptor that GABA
shares with glutamate is GAT, which mediates the uptake of both neurotransmitters. GAT
is present in glial cells and neurons. Four types of GAT transport GABA: GAT1, GAT2,
GAT3, and BGT-1. GABA transporters function by the gradients of Na+ and Cl−. GAT1
is the major GABA transporter, and it is mainly localized in the cerebral cortex, whereas
GAT3 is found in the brainstem. Otherwise, GAT2 is expressed in liver and kidney, and to
a lesser extent in the leptomeninges [116]. Because GABA is an inhibitory neurotransmitter,
decreasing its concentration would produce a feeling of anxiety. It has also been associated
with schizophrenia, autism spectrum disorder, and major depressive disorder.
5.2. GABA’s Role in the Gastrointestinal Tract
In the gastrointestinal tract, GABA has multiple functions such as visceral nocicep-
tion, modulation of colonic afferent excitability, gastrointestinal secretion, and motility or
enhancement of the local immune system [117]. The different GAT isoforms are present in
the gastrointestinal tract: GAT2 is predominantly localized in enteric glia cells and GAT3 in
myenteric neurons [118]. A GABAergic signal system in the intestinal epithelial cells has
been demonstrated and has a role in the pathogenesis of allergic diarrhoea by activation of
submucosal secretomotor neurons [113].
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As the main inhibitory neurotransmitter, GABA plays a protective role in inflammatory
diseases by modulating the production of cytokines. Actually, GABA levels are decreased
in serum samples of patients suffering from multiple sclerosis, ischaemic stroke, ulcerative
colitis, and other inflammatory diseases [119]. The GABAergic system is also altered in IBS
patients. IBS-D patients show diminished levels of GABA, GAD2, and GABA- B receptors
subtype B1 and B2, as well as increased GAT-2 [119]. Not only are GABA-B receptors
altered in IBS patients, but Selfi et al. have also demonstrated higher levels of GABA-A
receptor α3 in colon from mice exposed to stress, showing that stress could be responsible
for GABAergic alteration in IBS.
Hypersensitivity to visceral pain is a key IBS symptom. In this line, patients suffering
from chronic pelvic pain had lower levels of GABA in anterior cingulate cortex [120].
Moreover, anxiety disorders are comorbid pathologies highly related to IBS. GABA levels
in the prefrontal cortex appear to be increased in IBS patients with highly severe anxiety
symptoms, but not in IBS patients without comorbid anxiety disorders. However, these
GABAergic alterations are not related to gastrointestinal symptoms, pain or depression [96].
5.3. GABA as a Target for Treatment
GABA agonists or analogues such as pregabalin or gabapentin could be useful for IBS
treatment. As Zhang et al. proved, gabapentin improves pain and anxiety-like behaviours
in mice, although the pharmacological use of this drug for the treatment of IBS should be
limited due to its serious side effects (hepatotoxicity and neurotoxicity) [121]. Gabapentin
also demonstrated a reduction in the cerebral nociceptive response to colorectal distension.
The FDA has approved pregabaline for the treatment of fibromyalgia and neuropathic
pain for its analgesic and anxiolytic effects [122]. In IBS-D and IBS-M, pregabalin seems
to improve abdominal pain, diarrhoea, and bloating, but it did not affect the quality of
life, anxiety or depression, and IBS symptoms in IBS-C patients [122]. The improvement
of pregabalin in IBS symptoms may be explained by its binding to calcium channels of
the enteric neurons in the ileum [123]. The use of baclofen (a GABA-B receptor agonist)
and gabapentin has been investigated to reduce visceral sensitivity in rats. Baclofen can
decrease visceromotor response, but its effect does not seem to be significant and its side
effects do not allow its use as chronic treatment [124]. CGP7930 is another GABA-BR
agonist that can reduce visceral pain without as many side effects as baclofen due to
its mechanism of action, that enhances endogenous GABA release [118]. Despite being
a promising target for IBS treatment, activation of GABA-A receptors has also shown
important side effects such as exacerbation of acute colitis [125]. Other possible alternative
treatments for GABA-dependent gastrointestinal symptoms are the use of genetically
modified GAD-productor Bifidobacterium longum [126] or GABA containing functional
foods such as enriched goat milk [127].
6. Acetylcholine
Ach is an excitatory neurotransmitter that is named after its chemical structure con-
sisting of acetic acid and choline. Choline is present in dietary foods, and acetic acid
derives from mitochondrial coenzyme acetyl-coA. The synthesis of ACh takes place in axon
terminals and is catalysed by the enzyme choline-acetyl-transferase; then it is introduced in
synaptic vesicles by the vesicular ACh transporter. After its release and binding to nicotinic
or muscarinic receptors, ACh is degraded by acetylcholinesterase, mainly present in the
synaptic cleft. Once hydrolysed, choline returns to presynaptic neurons by the action of a
high-affinity choline transporter.
6.1. Acetylcholine’s in the Central Nervous System
ACh acts at various sites within the CNS, where it can function as a neurotransmitter
and as a neuromodulator. It plays a role in motivation, arousal, attention, learning, and
memory, and is involved in promoting REM sleep. ACh signalling can be mediated by
nicotinic and muscarinic receptors; nicotinic receptors are ion channel ligated, whereas
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muscarinic ones are ligated to G proteins. Nicotinic receptors are composed of 5 homolo-
gous subunits, but those localized in neuromuscular junctions consist of different subunits
that are different from neuronal ones. Although activation of nicotinic receptors shows
variable responses depending on the subunit composition, their activation usually pro-
duces membrane depolarization [128]. Among their functions, these receptors play a role in
enhancing neuromodulation and release of different neurotransmitters such as glutamate
and GABA [129]. They are especially vulnerable to the deposit of ß-amyloid peptide in the
pathogenesis of Alzheimer’s disease, manifesting a down-regulation of these receptors in
Alzheimer’s patients [129]. On the other hand, there are 5 subtypes of muscarinic receptors:
M1, M2, M3, M4, and M5 that can be classified into 2 groups, depending on their associated
G protein: M1, M3, and M5 are ligated to the family of Gq/11 proteins [130] and their
activation increases neuronal excitability [131], whereas M2 and M4 are joined to Gi/o-type
G proteins [130] and their activation produces postsynaptic inhibition [131]. Muscarinic
receptors are involved in memory, motor function and learning; in fact, M1 is associated
with cognitive processing, memory, and learning. M2 expression is decreased in patients
with Alzheimer’s disease and associated with the neuropsychiatric behaviour of these
patients [132].
ACh is known for its function as a key neurotransmitter and mediator of the commu-
nication between neurons and muscle cells, but it also plays an important role in the au-
tonomous nervous system regulating heart rate, digestion, breathing, or vasodilation [133].
The release of ACh in neocortical cells is associated with a state of vigilance, but in contrast,
Ach can also be key in sleep phases. The participation of ACh in cognitive function and
episodic as well as semantic memory is also recognized, especially in the hippocampus. In
both sites (hippocampus and neocortex), ACh enhances experience-dependent plasticity in
synergic action with NE [134]. In addition, ACh plays an important role as a neuromodu-
lator, enhancing neuronal responses to internal and external stimuli [133] Actually, ACh
enhances T cell migration into infected tissues in the immune response [135].
ACh’s functions mostly depend on its concentration. ACh concentration oscillates
with circadian rhythms, but other stimuli (as caffein or attentional demands) may trigger
variations in the concentration of ACh [136]. Alterations in the cholinergic system are
associated with the pathogenesis of different mental pathologies such as schizophrenia,
major depression, or bipolar disorder. In fact, ACh receptor antagonists and inhibitors
of acetylcholinesterase are used for the treatment of depressive symptoms and visual
hallucinations [129].
6.2. Acetylcholine’s Role in the Gastrointestinal System
In the gastrointestinal system, ACh is involved in colonic motility [137]. Higher levels
of ACh result in an increase in gastrointestinal motility [138], but a decrease in cholinergic
function in the elderly may explain their propensity to have constipation [137]. ACh also
modulates Cl- secretion, mainly via M3 muscarinic receptors and to a lesser extent M1
muscarinic receptors as well [139]. ACh is released from vagal efferent nerves then it joins
α7 nicotinic ACh receptors, inhibiting TNFα from macrophages and decreasing intestinal
permeability. Moreover, it is conjectured that vagus nerve stimulation by those receptors
could mediate a protective role in the intestinal epithelium barrier [140].
ACh may be involved in IBS pathophysiology, because IBS’s comorbidities (especially
anxiety disorders and stress) produce changes in ACh levels. Acute stress suppresses ACh
synthesis in the intestine and brain by inhibiting the production of choline acetyltrans-
ferase, and favouring the synthesis of acetylcholinesterase [141], which is associated with
an inflammatory effect due to the loss of inflammatory inhibition mediated by ACh [142].
In this context, some studies have shown that acute stress in maternally separated rats
with IBS results in increased colonic motility, mediated by ACh [143]. This may be clini-
cally translated into augmentation of stool frequency. Furthermore, blocking muscarinic
receptors with atropine inhibits stress-induced diarrhea [144]. In contrast, IBS-C patients
showed no differences in the secretory response of colonic mucosa to acetylcholine [145].
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Because it is recognized that the development of IBS and other gastrointestinal diseases is
joined to early life stress, changes in the cholinergic system were studied in pigs exposed
to early weaning stress. Compared to controls, an upregulation of the cholinergic activity
in early weaning stress pigs was expressed as the absence of decrease of ChAT neurons in
the GI tract [146].
6.3. Acetylcholine as a Target for Treatment
Mediators of colonic mucosa in IBS patients have been demonstrated to activate ACh
release from myenteric neurons via mast cells independently of the bowel habit [147].
Hyperalgesia and visceral hypersensitivity have been associated with increased expression
of high-affinity choline transporter (HAChT) [148]. This augmentation can result in an
increase in ACh levels, which has an antinociceptive role [149]. Pharmacological modifica-
tions of the upregulation of HAChT have been done with ammonium pyrrolidinedithio-
carbamate, which abolishes this phenomenon. Moreover, MKC-231 can enhance HAChT
activity, resulting in a decrease in visceral pain [150]. Most of the investigated drugs with
cholinergic effects in the treatment of IBS reduce colonic motility and stool frequency. Mus-
carinic antagonists (e.g., dicyclomine) inhibit colonic contractility, which can be an effective
way to manage symptoms such as abdominal pain and diarrhoea [151]. In Australia, the
utilization of mebeverine is approved for the treatment of alterations in the bowel transit
and abdominal pain. Mebeverine acts as an antagonist of muscarinic receptors and an
inhibitor of NE uptake [152]. Pinaverium is also prescribed for the same gastrointestinal
symptoms, because its anticholinergic effect only takes place on smooth intestinal muscle,
reducing systemic effects [153]. Recent studies have demonstrated the potential use of
selective M3-antagonists. Darifenacin may regulate gastrointestinal motility in a manner
more pronounced than is seen in non-selective antagonists such as tolterodine. In fact, in
patients with IBS-D, darifenacin causes a significant delay of intestinal and colonic transit
compared to alosetron [154]. Tolterodine is nowadays used for the treatment of overactive
bladder. As a muscarinic receptor antagonist, one of its main side effects is constipation,
although it is proven that no differences in bowel transit occur with placebo [155]. More-
over, anticholinergic drugs used for the treatment of overactive bladder were tested in
different intestinal diseases resulting in an improvement of IBS symptoms [156]. Another
muscarinic antagonist used for the treatment of IBS is zamifenacin (a partially selected
M3 antagonist), which reduces postpandrial colonic contractility [157]. Apart from the
use and research of drugs acting on muscarinic receptors, other drugs that target different
receptors have also been studied. Cannabinoid receptors are in cholinergic neurons; thus,
cannabinoid agonists also have cholinergic effects. Dronabinol (a cannabinoid receptor
agonist) has been probed in IBS patients, showing a reduction in gastrointestinal motility
and gain in colonic compliance in IBS-D and IBS-M subtypes but not in IBS-C [158]. In
addition, some serotonin antagonists also have anticholinergic effects, including alosetron,
ramosetron, cilansetron, ondansetron, and granisetron; they can reduce gastrointestinal
peristalsis and upgrade abdominal pain [159].
7. Other Neurotransmitters
Here we have explored the role of main neurotransmitters in IBS, but the involvement
of other neurotransmitters cannot be neglected. Several studies have pointed out the
potential role of histamine and dopamine in IBS pathogenesis.
Histamine has been related to gastrointestinal inflammation and abdominal pain. The
main histamine receptors, which take part in gastrointestinal processes, are H1 and H4,
although H2 is related to the production of gastric acid [160]. In IBS patients, levels of
urinary histamine have correlated to the severity of IBS symptoms, especially abdominal
pain [161]. The administration of an H1-antagonist revealed different responses in IBS
patients compared to healthy controls, demonstrating possible overstimulation of the
histaminergic system in IBS patients [162]. H1 and H4 receptors could have a key role
in the pathogenesis of colitis and postinflammatory visceral hypersensitivity, because
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their expression is increased in colon tissue of rats that have colitis. JNJ7777120, an
H4-antagonist, seemed to ameliorate abdominal pain in that postinflammatory colitis
model [163]. Novel interventions are being proposed that involve blocking H1 receptors,
as ebastine has been found to improve IBS symptoms, including visceral hypersensitivity
and abdominal pain [164], and ketotifen has been found to enhance health-related quality
of life and increase the pain threshold in IBS patients [165]. Similarly, AST-12O, which
adsorbs histamine from the intestinal lumen, could reduce pain and bloating in IBS-D and
IBS-M patients [166].
On the other hand, several studies have investigated alterations in the dopaminergic
system in IBS patients. In fact, IBS patients show lower dopamine levels in plasma [51]
and urine [161] compared to healthy controls. Dopamine mediates colonic peristalsis,
activating muscle contraction through D1 receptors and inhibiting it by D2 receptors [167],
being related to motility dysfunction. However, the administration of dopamine or its
agonists enhances IBS symptoms in patients with comorbid restless legs syndrome [168].
Nowadays, metformin is a widely used drug for the treatment of mellitus diabetes type
II. Nevertheless, this drug has been studied for its antinociceptive effect through the
activation of central D2 dopamine receptors in IBS patients [169]. Similarly, activation of
those dopaminergic receptors by butyrate enemas decreases visceral allodynia and colonic
hyperpermeability [170].
8. Conclusions
Managing IBS has attracted major attention because single-agent therapy rarely re-
lieves bothersome symptoms for all patients. In clinical practice, there is still a lack of
effective treatment for IBS, and the prescribed drugs usually alleviate only one symptom
of the whole syndrome. IBS patients display some neurotransmitter dysfunctions that
could cause disruption of gut homeostasis and the onset of gastrointestinal symptoms such
as abdominal pain, bloating and changes in stool frequency in IBS. A more exhaustive
personalized analysis in relation to neurotransmitters in IBS patients would be necessary
to develop strategies that are more effective and achieve a better understanding of the role
of the gut-brain axis in the pathogenesis of the syndrome.
Here, we have evaluated the current evidence of neurotransmitter dysfunction in IBS
and explored its potential therapeutic use. Dysfunctions of key neurotransmitters such as
norepinephrine, serotonin, glutamate, GABA, or acetylcholine could help to understand
IBS pathophysiology and open the door of new approaches for IBS management.
Some drugs focused on neurotransmitters are being explored for the management
of IBS symptoms (Table 1), however, the interaction between different neurotransmitters
should be considered. Even if evidence of improvement of IBS symptoms exists, new
targets and therapies are needed. In this context, finding novel targets for specific neu-
rotransmitters’ receptors to reduce side effects is critical. The use of antidepressants for
the treatment of IBS is controversial due to their adverse effects. SSRIs improve psycho-
logical symptoms in depressive and anxiety disorders, but their effect on gastrointestinal
symptoms is limited. Individualized treatment could be an alternative for patients with
comorbid anxiety or depressive disorders. The development of more selective molecules
as isoform-targeted agonists and antagonists of serotonin receptors [171] would provide
novel approaches with minimal side effects. In addition, we cannot forget the effect of diet
on the production and metabolism of neurotransmitters [172].
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Table 1. Summary of the drugs targeting neurotransmitters used in IBS.
Neurotransmitter Drug Receptor Effect Pharmacological Use References
SEROTONIN
CISAPRIDE 5-HT4 agonist and5-HT3 antagonist
Prokinetic






TEGASEROD 5-HT4 agonist Prokinetic Use for the treatment of IBS-C
Crowell et al.
2001 [66]
VELUSETRAG 5-HT4 agonist Prokinetic




PRUCALOPRIDE 5-HT4 agonist Prokinetic




ALOSETRON 5-HT3 antagonist Decreases GI motility






abdominal pain Used as antiemetic
Min et al.
2015 [70]











PREGABALIN GABA analogous Analgesic andanxiolytic




GABAPENTIN GABA analogous Analgesic andanxiolytic




CGP7930 GABA-B receptoragonist Reduces visceral pain








Use for the treatment of


































TOLTERODINE Non-selectivemuscarinic antagonist Induces constipation








Approved in Australia for
IBS treatment
Dumitrascu
et al. 2014 [152]
DARIFENACIN M3 antagonist Improves IBSbowel habits
Use for the treatment of
overactive bladder syndrome
De Schryver
et al. 2000 [154]
PINAVERIUM Anticholinergic effect Antispasmodic





Finally, numerous pieces of evidence suggest that changes in the microbiota are cor-
related with the development of visceral hypersensitivity, which represents one of the
major symptoms in IBS patients [172]. Recent studies have demonstrated the crucial
inter-relationship between bacteria and neurotransmitters. Gut microbiota can produce
neurotransmitters, modulate host production and even regulate their signalling. Therefore,
more studies addressing the microbiota-gut-brain axis in the IBS context are needed. An
innovative and intriguing approach has been opened by the possibility of modulating neu-
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rotransmitter signalling along the microbiota-gut-brain axis by influencing the microbiota
composition [61]. Microbiota modulation by probiotics, prebiotics or faecal transplantation
could bring new approaches for IBS management. In fact, a randomized, double-blind,
placebo-controlled trial showed improved diversity of microbiota in faecal transplantation
IBD patients [173]. Promising results concerning probiotics as a new approach to IBS
have also been obtained [173]. Research in this field opens an exciting scenario on the
possibility of targeting neurotransmitter signalling, by means of traditional pharmacologi-
cal approaches as well as by microbiota modulation as new potentially therapeutic tools
addressed to irritable bowel syndrome.
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